Jia-Ning Xiang

This inventor holds 77 USPTO granted patents and 4 published patent applications, plus 3 CIPO patents and 7 EPO patents, primarily in Pharmaceutical Compositions (CPC class C07C). Top assignees: Xenoport, Inc., Smithkline Beecham Corporation, Xwpharma Ltd.. Active years: 1998-2023.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Jia-Ning Xiang. Retrieved from https://idiyas.com/inventor/jia-ning-xiang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 77 (Patent Applications = 4)

% Patents Active = 57.1

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 7 (Patent Applications = 4)

Average Co-Inventor Count = 4.0

ph-index = 22

Forward Citations = 1,142(Granted Patents)

Forward Citations (Not Self Cited) = 955(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Wayne, PA (US) (1998 - 2004)
Shanghai, CN (2011)
Palo Alto, CA (US) (2004 - 2020)
Hubei, CN (2020)
Wuhan, CN (2020 - 2023)
Fremont, CA (US) (2022 - 2023)

Company Filing History:

Smithkline Beecham Corporation

where one patent can have more than one assignee

Years Active: 1998-2023

Loading Chart...

Areas of Expertise:

Nuclear Transport Modulators

Reactive Oxygen Species

Ketamine Derivatives

Prodrugs

Bicyclic Heteroaryl Derivatives

Neuronal Histamine Receptor-3

Pharmacokinetics

Gamma-Hydroxybutyric Acid

Oral Dosage Forms

Controlled Release

Water-Soluble Ingredients

Neurokinin-1 Receptor Antagonists

77 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11767313 - Compounds as nuclear transport modulators and uses thereof (2023-09-26),

2. 11746081 - Methods of synthesizing 4-valyloxybutyric acid (2023-09-05),

3. 11692008 - Preparation and uses of reactive oxygen species scavenger derivatives (2023-07-04),

4. 11690811 - Pharmaceutical compositions and oral dosage forms of ketamine derivatives (2023-07-04),

5. 11639337 - Bicyclic heteroaryl derivatives and preparation and uses thereof (2023-05-02),

6. 11510892 - Pharmacokinetics of combined release formulations of a γ-hydroxybutyric acid derivative (2022-11-29),

7. 11440874 - Ketamine derivatives and compositions thereof (2022-09-13),

8. 11420955 - Compounds as neuronal histamine receptor-3 antagonists and uses thereof (2022-08-23),

9. 11401249 - Bicyclic heteroaryl derivatives and preparation and uses thereof (2022-08-02),

10. 11395801 - Modified release compositions of a gamma-hydroxybutyric acid derivative (2022-07-26),

11. 11357734 - Pharmaceutical granulations of water-soluble active pharmaceutical ingredients (2022-06-14),

12. 11312703 - Reactive oxygen species scavengers and use for treating diseases (2022-04-26),

13. 11304906 - Controlled release granulations of water-soluble active pharmaceutical ingredients (2022-04-19),

14. 11279669 - Methods of synthesizing 4-valyloxybutyric acid (2022-03-22),

15. 11149006 - Compounds as neurokinin-1 receptor antagonists and uses thereof (2021-10-19),

Title: Jia-Ning Xiang: Innovator in Nuclear Transport Modulators

Introduction

Jia-Ning Xiang is a prominent inventor based in Palo Alto, CA, with an impressive portfolio of 77 patents to his name. His work primarily focuses on the development of innovative compounds and methods that have significant implications in the fields of neurology and oncology.

Latest Patents

Among his latest patents is the disclosure of compounds as nuclear transport modulators. These novel nuclear transport modulators can inhibit transporters such as the exportin-1 transporter, offering potential therapeutic avenues for treating neurological diseases and cancer. Additionally, Xiang has developed synthetic methods for the preparation of 4-valyloxybutyric acid, incorporating diverse protecting group strategies and reaction conditions. This work also includes compounds that serve as synthetic intermediates essential for the production of 4-valyloxybutyric acid.

Career Highlights

Throughout his career, Jia-Ning Xiang has made substantial contributions to pharmaceutical innovation. He has held key positions in reputable companies, including Xenoport, Inc. and SmithKline Beecham Corporation, where he has applied his expertise in research and development to drive advancements in drug design and synthesis.

Collaborations

In his professional journey, Xiang has collaborated with notable scientists such as Cindy X Zhou and Mark A Gallop, contributing to a dynamic exchange of ideas and fostering innovation in their respective projects.

Conclusion

Jia-Ning Xiang exemplifies the spirit of innovation in the life sciences sector. Through his pioneering patents and collaborative efforts, he continues to influence the landscape of therapeutic development, with a focus on addressing challenging medical conditions. His work paves the way for future advancements that may significantly enhance patient care and treatment options.

Profile summary based on public USPTO records.